Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
Date:2/26/2009

SAN DIEGO, Feb. 26 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the fourth quarter and year-ended December 31, 2008.

"2008 was a very productive year at Anadys," said Steve Worland, Ph.D., Anadys' President and CEO. "We resumed clinical development activities and positioned our HCV programs for viral load data, which we now have begun to see. We have established ANA598 as a potent antiviral, demonstrating in three days a greater viral load decline as a single agent than has been reported for any other non-nucleoside polymerase inhibitor. And today we are reporting that we have seen preliminary indications of antiviral activity with ANA773, our oral inducer of endogenous interferons that acts via the TLR7 pathway. We believe that ANA598, and potentially ANA773, hold promise to become important parts of future combination regimens to treat HCV patients."

Financial Results

As of December 31, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $27.9 million.

During the fourth quarter of 2008 the Company had no revenue, compared to $0.2 million for the same quarter of 2007. The revenue in the fourth quarter of 2007 was primarily derived from the successful completion of our screening collaboration with Aphoenix, Inc.

Research and development expenses were $6.9 million for the fourth quarter of 2008 and 2007. During the fourth quarter of 2008, cost savings derived from Anadys' completed strategic restructuring were offset by significant increases in development costs for ANA598 and ANA773.

Gener
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
2. Anadys Pharmaceuticals to Present at Bio Investor Forum
3. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
4. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
5. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 The discounts that some ... products do not include various skin creams or oil ... skin tightening cream discounts inside of its cost saving ... is now available to offer a direct source for ... products available for sale. Although the guide includes pricing, ...
(Date:7/23/2014)... Men and women who are married ... insurance based on national averages. The Quotes Pros company ... to its comprehensive tool this year to help married ... , Providers that are now underwriting plans on a ... one or two clicks. The intelligent platform used to ...
(Date:7/23/2014)... July 23, 2014 The puffiness that ... using non-surgical techniques, according to a new guide published ... serum sold in the U.S. is now available for ... , The complimentary guide that is now published is ... with under eye puffiness. While surgical techniques are available, ...
(Date:7/23/2014)... 2014 Recently, iFitDress.com, a professional company of ... of 2014 vintage party dresses . Aside from that, ... current discount is up to 63% off. , “We are ... These new items are all manufactured by trustworthy and experienced ... until July 30; it is great to provide such a ...
(Date:7/23/2014)... 23, 2014 In preparation for National ... Millennium Treatment Group is providing tips on choosing a ... society ever since man first figured out the process ... has existed since shortly thereafter. Its basis lies in ... then developing a way to combat that problem while ...
Breaking Medicine News(10 mins):Health News:Skin Tightening Cream Discounts Revealed in New Cost Saving Guide at Consumer Portal 2Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Puffy Eyes Serum Explored in Complimentary Guide Released at Consumer News Website 2Health News:Cheap 2014 Vintage Party Dresses From Professional Supplier iFitDress.com 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3
... embryos or adult mice to behave like stem cells ... in an immediate early publication of the journal Cell. ... stem cells" (iPS) behaved physically and genetically as stem ... used to treat a host of diseases, such as ...
... a ban on Coke and Pepsi by the Kerala Government, the ... forth a proposal to stop the sale// and production of 11 ... ,Top brass in the companies are very unhappy over these moves, ... company which is not in sync with the reports from ...
... has called for moratoriums on consumer advertising which promotes ... that the products// are safe and that they work. ... group has urged the U.S. Food and Drug Administration ... after a drug or device obtains regulatory approval before ...
... found in a study that instead of dieting, which could ... and thereby a desire// to change it, women who accept ... lowest body mass index (BMI). ,The researchers have ... disorders. Tracy Tylka, assistant professor of psychology and one of ...
... is a rare condition that affects children as well ... named anakinra could alleviate// symptoms and bring down the ... in the August 10 issue of the New England ... Research Program of the National Institute of Arthritis and ...
... a sharp rise in polio cases in the country with ... as against a total of 66 last year.// ... upper house, Friday that the transmission of poliovirus may continue ... target". ,In a written answer he said that ...
Cached Medicine News:Health News:Only A Few Differentiating Factors Between Adult And Stem Cells 2Health News:Drug Advertising needs to be Limited 2Health News:Study Finds Healthier Women Are Those Who Accept The Way They Look 2Health News:NOMID Symptoms Helped By Arthritis Drug 2Health News:NOMID Symptoms Helped By Arthritis Drug 3
(Date:7/23/2014)... 23, 2014  Dompe, a leader in R&D for new ... rhNGF (Recombinant Human Nerve Growth Factor) has been designated as ... (FDA). The candidate drug, developed by the ... for the treatment of neurotrophic keratitis, a degenerative corneal disease ... and is currently without a cure. This is the second ...
(Date:7/23/2014)... 2014 Research and Markets ... Medical Kits and Trays - Global Strategic Business ... http://photos.prnewswire.com/prnh/20130307/600769 This ... Kits and Trays in US$ Thousands by the ... Trays, Custom Basin Kits, Custom Ob/Gyn Kits, General ...
(Date:7/23/2014)... 2014  ArmaGen, a privately held biotechnology company ... neurological disorders, announced today that it has entered ... Shire plc to develop AGT-182, an investigational enzyme ... the central nervous system (CNS) and somatic (body-related) ... II, Hunter syndrome is a rare, severe, progressive ...
Breaking Medicine Technology:Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4Prepackaged Medical Kits and Trays - Global Strategic Business Report: Updated 2014 Report 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 3
... Model 3085 temporary pacemaker is designed to ... for temporary atrial or ventricular or A-V ... where such pacing modes are indicated for ... Model 3085 can be used to measure ...
... a unique left ventricular assist device that helps ... being used in a small group of patients ... of an FDA-approved Feasibility Study. The patient can ... power source for minutes or hours. The Kantrowitz ...
... system provides an ideal solution for ... laboratory, satellite lab and the clinic ... method with wedge-smear technology, the ADVIA ... in a safe enclosed environment. The ...
... T600 treadmill has streamlined design, ... a brushless DC motor and ... unique system that operates on ... in smooth operation, remarkably low ...
Medicine Products: